Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/30/2025

Promethazine Mechanism and Administration

Primary Indications

  • The American Gastroenterological Association recommends promethazine as an adjunct for sedation during minor surgical and endoscopic procedures 1, 2

Pharmacology and Administration

  • Promethazine blocks postsynaptic dopaminergic receptors in the brain, has strong adrenergic inhibitory effects, acts as a competitive histamine H1-receptor antagonist, and possesses anticholinergic effects 1, 2
  • Intravenous dosing of promethazine is 12.5-25 mg, infused slowly to minimize hypotension risk, with a total dose of 25-100 mg used as an adjuvant to narcotics and benzodiazepines 1
  • Clinical effects of promethazine are evident within 5 minutes of intravenous administration, with a duration of action of 4-6 hours and a plasma half-life of 9-16 hours 1

Adverse Effects and Precautions

  • Hypotension, particularly with rapid IV administration, is a common adverse effect of promethazine 1, 2
  • Respiratory depression is a potential adverse effect of promethazine 1
  • Dizziness, blurred vision, and dry mouth are common adverse effects of promethazine 3
  • Neuroleptic malignant syndrome and extrapyramidal effects are serious adverse effects of promethazine 1

Special Populations

  • The American Academy of Pediatrics warns of fatal respiratory depression in children younger than 2 years taking promethazine 4

Clinical Considerations

  • Promethazine has been successfully administered in combination with meperidine for endoscopic procedures 1
  • The National Comprehensive Cancer Network recommends promethazine 12.5-25 mg PO or IV every 4 hours for breakthrough treatment of chemotherapy-induced nausea/vomiting 5
  • Promethazine may be beneficial as an antihistamine option for patients with opioid-induced pruritus 6

Promethazine Use in Nausea and Vomiting Management

Primary Clinical Indications

  • The American Gastroenterological Association recommends using promethazine 12.5-25 mg orally or IV every 4-6 hours when ondansetron or other 5-HT3 antagonists fail to control symptoms 7, 8
  • Promethazine 12.5-25 mg by mouth or rectally every 4-6 hours is specifically recommended as abortive therapy during acute cyclic vomiting syndrome episodes 7

Postoperative Nausea and Vomiting

  • The American Society of Anesthesiologists demonstrates that promethazine is effective for prophylaxis of postoperative nausea and vomiting, with evidence supporting reduced nausea and vomiting compared to placebo 9
  • Consider promethazine for prophylaxis in patients with prior history of postoperative nausea, particularly when sedation is beneficial 9, 10

Critical Safety Considerations

  • The National Comprehensive Cancer Network notes that CNS depression and sedation occur frequently with promethazine use, which may be advantageous when sedation is desired but problematic otherwise 7, 10
  • Extrapyramidal symptoms can develop with promethazine use, similar to other dopamine antagonists 7, 11

Special Clinical Contexts

  • The National Comprehensive Cancer Network recommends promethazine for opioid-induced nausea when prophylaxis is needed in patients with prior history 8, 10
  • The World Journal of Emergency Surgery suggests that promethazine serves as an appropriate option targeting dopaminergic pathways for refractory nausea in palliative care settings 11